Literature DB >> 29715200

TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.

Ramesh Singh1, Dileep Karri1, Hong Shen1, Jiangyong Shao2, Subhamoy Dasgupta1, Shixia Huang1,3, Dean P Edwards1,4, Michael M Ittmann4,5, Bert W O'Malley1, Ping Yi1.   

Abstract

Receptor tyrosine kinases (RTKs) are important drivers of cancers. In addition to genomic alterations, aberrant activation of WT RTKs plays an important role in driving cancer progression. However, the mechanisms underlying how RTKs drive prostate cancer remain incompletely characterized. Here we show that non-proteolytic ubiquitination of RTK regulates its kinase activity and contributes to RTK-mediated prostate cancer metastasis. TRAF4, an E3 ubiquitin ligase, is highly expressed in metastatic prostate cancer. We demonstrated here that it is a key player in regulating RTK-mediated prostate cancer metastasis. We further identified TrkA, a neurotrophin RTK, as a TRAF4-targeted ubiquitination substrate that promotes cancer cell invasion and found that inhibition of TrkA activity abolished TRAF4-dependent cell invasion. TRAF4 promoted K27- and K29-linked ubiquitination at the TrkA kinase domain and increased its kinase activity. Mutation of TRAF4-targeted ubiquitination sites abolished TrkA tyrosine autophosphorylation and its interaction with downstream proteins. TRAF4 knockdown also suppressed nerve growth factor (NGF) stimulated TrkA downstream p38 MAPK activation and invasion-associated gene expression. Furthermore, elevated TRAF4 levels significantly correlated with increased NGF-stimulated invasion-associated gene expression in prostate cancer patients, indicating that this signaling axis is significantly activated during oncogenesis. Our results revealed a posttranslational modification mechanism contributing to aberrant non-mutated RTK activation in cancer cells.

Entities:  

Keywords:  Cell Biology; Genetics; Prostate cancer; Protein kinases; Ubiquitin-proteosome system

Mesh:

Substances:

Year:  2018        PMID: 29715200      PMCID: PMC6026011          DOI: 10.1172/JCI96060

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  73 in total

1.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  TRAF4 overexpression is a common characteristic of human carcinomas.

Authors:  S Camilleri-Broët; I Cremer; B Marmey; E Comperat; F Viguié; J Audouin; M-C Rio; W-H Fridman; C Sautès-Fridman; C H Régnier
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

3.  Ligand-induced downregulation of TrkA is partly regulated through ubiquitination by Cbl.

Authors:  Yuga Takahashi; Noriaki Shimokawa; Saeed Esmaeili-Mahani; Akihito Morita; Hiroko Masuda; Toshiharu Iwasaki; Jun'ichi Tamura; Kaisa Haglund; Noriyuki Koibuchi
Journal:  FEBS Lett       Date:  2011-05-09       Impact factor: 4.124

4.  Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.

Authors:  Claudio Festuccia; Paola Muzi; Giovanni Luca Gravina; Danilo Millimaggi; Silvia Speca; Vincenza Dolo; Enrico Ricevuto; Carlo Vicentini; Mauro Bologna
Journal:  Int J Oncol       Date:  2007-01       Impact factor: 5.650

5.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

6.  Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling.

Authors:  Thangiah Geetha; Jianxiong Jiang; Marie W Wooten
Journal:  Mol Cell       Date:  2005-10-28       Impact factor: 17.970

Review 7.  Targeting E3 ubiquitin ligases for cancer therapy.

Authors:  Yi Sun
Journal:  Cancer Biol Ther       Date:  2003 Nov-Dec       Impact factor: 4.742

8.  TRAF4 enhances oral squamous cell carcinoma cell growth, invasion and migration by Wnt-β-catenin signaling pathway.

Authors:  Jianbin Yang; Dongyi Wei; Weixin Wang; Baohong Shen; Suling Xu; Yuan Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Authors:  Victor D Acevedo; Rama D Gangula; Kevin W Freeman; Rile Li; Youngyou Zhang; Fen Wang; Gustavo E Ayala; Leif E Peterson; Michael Ittmann; David M Spencer
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

10.  Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis.

Authors:  R Singh; S C Gupta; W-X Peng; N Zhou; R Pochampally; A Atfi; K Watabe; Z Lu; Y-Y Mo
Journal:  Cell Death Dis       Date:  2016-06-09       Impact factor: 8.469

View more
  23 in total

1.  Novel interaction of antioxidant-1 with TRAF4: role in inflammatory responses in endothelial cells.

Authors:  Archita Das; Varadarajan Sudhahar; Masuko Ushio-Fukai; Tohru Fukai
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-25       Impact factor: 4.249

2.  TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.

Authors:  Liulin Tang; Min Wang; Li Jiang; Chengying Zeng
Journal:  Hum Cell       Date:  2020-05-09       Impact factor: 4.174

3.  Ring finger protein 5 activates sterol regulatory element-binding protein 2 (SREBP2) to promote cholesterol biosynthesis via inducing polyubiquitination of SREBP chaperone SCAP.

Authors:  Yen-Chou Kuan; Yu Takahashi; Takashi Maruyama; Makoto Shimizu; Yoshio Yamauchi; Ryuichiro Sato
Journal:  J Biol Chem       Date:  2020-02-13       Impact factor: 5.157

4.  Curcumin prevents obesity by targeting TRAF4-induced ubiquitylation in m6 A-dependent manner.

Authors:  Yushi Chen; Ruifan Wu; Wei Chen; Youhua Liu; Xing Liao; Botao Zeng; Guanqun Guo; Fangfang Lou; Yun Xiang; Yizhen Wang; Xinxia Wang
Journal:  EMBO Rep       Date:  2021-04-20       Impact factor: 8.807

5.  The E3 ligase TRAF4 promotes IGF signaling by mediating atypical ubiquitination of IRS-1.

Authors:  Wenjuan Yu; Ramesh Singh; Zhao Wang; Bert W O'Malley; Ping Yi
Journal:  J Biol Chem       Date:  2021-05-13       Impact factor: 5.157

Review 6.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

7.  TRAF4 positively regulates the osteogenic differentiation of mesenchymal stem cells by acting as an E3 ubiquitin ligase to degrade Smurf2.

Authors:  Jinteng Li; Peng Wang; Zhongyu Xie; Shan Wang; Shuizhong Cen; Ming Li; Wenjie Liu; Su'an Tang; Guiwen Ye; Guan Zheng; Hongjun Su; Mengjun Ma; Xiaohua Wu; Yanfeng Wu; Huiyong Shen
Journal:  Cell Death Differ       Date:  2019-05-10       Impact factor: 15.828

8.  Nerve Growth Factor Induces Proliferation and Aggressiveness In Prostate Cancer Cells.

Authors:  Marzia Di Donato; Gustavo Cernera; Antimo Migliaccio; Gabriella Castoria
Journal:  Cancers (Basel)       Date:  2019-06-06       Impact factor: 6.639

Review 9.  Genetic Alterations of TRAF Proteins in Human Cancers.

Authors:  Sining Zhu; Juan Jin; Samantha Gokhale; Angeli M Lu; Haiyan Shan; Jianjun Feng; Ping Xie
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

10.  TRAF4 acts as a fate checkpoint to regulate the adipogenic differentiation of MSCs by activating PKM2.

Authors:  Shuizhong Cen; Jinteng Li; Zhaopeng Cai; Yiqian Pan; Zehang Sun; Zhaofeng Li; Guiwen Ye; Guan Zheng; Ming Li; Wenjie Liu; Wenhui Yu; Shan Wang; Zhongyu Xie; Peng Wang; Huiyong Shen
Journal:  EBioMedicine       Date:  2020-04       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.